Tazverik Approved to Treat Metastatic, Locally Advanced Epithelioid Sarcoma

FRIDAY, Jan. 24, 2020 — Tazverik (tazemetostat) has received the first approval for treatment of adults and pediatric patients 16 years and older with metastatic or locally advanced epithelioid sarcoma that cannot be resected, the U.S. Food and…
Source: Topamax